Keros Therapeutics, Inc. (KROS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$11.31+1.25%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Revenue stabilizes or improves from current decline trajectory: FY27 revenue est -13.1% YoY vs -10.0% target.
Keros Therapeutics focuses on novel treatments for blood and muscle diseases. Management aims to fund operations through mid-2028, ensuring runway for development. The company has shown some positive earnings beats and is cheap compared to peers. Recent share buybacks signal confidence.
The company is loss-making with negative earnings expected to continue. Revenue is forecast to decline about 31% next year. Recent earnings misses and downward estimate revisions show execution risks. Funding beyond mid-2028 is uncertain.
The market prices in a 31% revenue decline and a 58% discount to our valuation range. This reflects skepticism about near-term growth and profitability. Our view differs by focusing on the potential to sustain operations through 2028 and eventual clinical progress.
Breaks if: Cash runway falls short of mid-2028
Maintain sufficient cash and cash equivalents to fund operating expenses and capital expenditures into the first half of 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment focused on the biotechnology sector. The current thesis state is cautious, given the recent financial performance and elevated near-term risks.
The market seems to have priced in a low expectations gap, suggesting that KROS is viewed as relatively cheap compared to its peers. However, the valuation is under pressure due to ongoing losses and recent earnings misses.
Fundamentals may remain weak in the near term, especially given the elevated risk of another earnings miss. Management's focus on funding operations and advancing clinical trials indicates a mixed outlook for execution.
The long-term thesis hinges on the company's ability to meet clinical milestones and manage operating expenses effectively. Additionally, performance of sector leaders and broader economic conditions will significantly influence KROS's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about future performance. There are no new supportive factors to offset this weakness.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents declined from $287.4 million at 2025-Q4 to $257.6 million at 2026-Q2. Management consistently expects this cash runway to fund operating expenses and capital expenditures into the first half of 2028, indicating delivery on this capital allocation priority.
“Based on current operating assumptions, Keros expects that its cash and cash equivalents as of June 30, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into…”
“Keros expects that its cash and cash equivalents as of March 31, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the first half of 2028.”
“Based on current operating assumptions, Keros expects that its cash and cash equivalents as of December 31, 2025 will enable the Company to fund its planned operating expenses and capital expenditure…”
Breaks if: EPS loss worsens or remains flat through FY27
Breaks if: Revenue decline exceeds -10% YoY in FY27
KROS is navigating a challenging environment with mixed management execution and elevated risks. Monitoring sector trends and management's ability to deliver on priorities will be crucial. Not investment advice.